Shingo Nakayamada

Jul 27, 2024 | arthritis-research.biomedcentral.com | Sae Ochi |Koshiro Sonomoto |Shingo Nakayamada |Yoshiya Tanaka

This study analyzed the factors associated with improvement of HAQ-DI and reduction of subjective pain among RA patients who achieved LDA within 6 months and one year of treatment. The results showed that the pretreatment background and treatment options were both associated with the improvement.

Jan 11, 2024 | ard.bmj.com | Hiroaki Tanaka |Yukinori Okada |Shingo Nakayamada |Yusuke Miyazaki

IntroductionAutoimmune rheumatic diseases (AIRDs) are systemic diseases characterised by orchestration of disrupted self-tolerance of immune systems, including rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE).1 2 Given shared immunological backgrounds across AIRDs, glucocorticoid and immunosuppressive drugs have been conventionally used for treatment.

Oct 30, 2023 | ard.bmj.com | Hiroaki Tanaka |Yukinori Okada |Shingo Nakayamada |Yusuke Miyazaki

DiscussionsIn this study, we evaluated the large-scale and cohort-based immunophenotype dataset over 1000 individuals and 11 AIRDs with deep and longitudinal clinical information.

Sep 19, 2023 | ard.bmj.com | Yuichi Ishikawa |Kei Tokutsu |Shingo Nakayamada |Aya Kuchiba

AbstractObjectives Life-threatening antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) with rapidly progressive glomerulonephritis (RPGN) and/or alveolar haemorrhage (AH) has a poor prognosis. Rituximab (RTX) is as effective as cyclophosphamide (CY) in remission induction therapy; however, the effectiveness and safety of RTX have not been established in life-threatening AAV.

Jul 20, 2023 | tandfonline.com | Shingo Nakayamada |Yoshiya Tanaka

ABSTRACTIntroduction Glucocorticoids and immunosuppressants are used to treat systemic lupus erythematosus (SLE). However, patients with SLE have poor long-term prognoses. This can be attributed to organ damage caused by flare-ups and drug toxicity due to the administration of nonspecific treatment. Therefore, SLE should be treated using therapeutic agents specific to its pathology. Janus kinase (JAK) inhibitors exert multitargeted effects by blocking the signaling of multiple cytokines.